McLean Hospital

Ketogenic Diet Shows Promise in Treating Serious Mental Illness in Stanford Medicine Study

Retrieved on: 
Monday, April 1, 2024
Overweight, Metabolism, Adipose tissue, Obesity, Schizophrenia, Dyslipidemia, McLean Hospital, Weight gain, Patient, SAN, Mental health, Sleep, Research, University, MD, Quality of life, Eating disorder, DSM-IV codes, Insulin resistance, Body mass index, Clinical trial, Metabolic syndrome, University of Edinburgh, Rethinking, Mood disorder, Psychiatry Research, Ketosis, Waist, BMI, Pharmaceutical industry

SAN MATEO, Calif., April 1, 2024 /PRNewswire/ -- The field of psychiatry may have a new ally in the form of a medical ketogenic diet, according to the findings of a pioneering pilot study published in Psychiatry Research and announced today by Stanford Medicine. The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965. 

Key Points: 
  • The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965.
  • The results offer compelling evidence of the potential benefits of ketogenic dietary therapy in this population.
  • Key findings of the single-arm pilot trial include:
    100% of participants who met the criteria for metabolic syndrome were in remission by the end of the study.
  • Dr. Sethi shared: "These results are encouraging and suggest that a ketogenic diet intervention could serve as a valuable adjunctive treatment for individuals living with serious mental illness.

BrainCheck Appoints Aaron Greenstein, MD to Clinical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Report, Dementia, Caregiver, The Wall Street Journal, Research, McLean Hospital, Geriatric psychiatry, Massachusetts General Hospital, Ageing, MD, New York Medical College, CO, Human services, Mass, Mass General Brigham, Harvard Review of Psychiatry, Growth, Patient, MGH, News, Policy, Nursing

AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise. Dr. Greenstein, who has worked for some of the most prestigious academic facilities and influential senior healthcare startups, joins the Company as Clinical Advisor following the recent launch of its next-generation platform and 3-minute screening tool, expanding the first end-to-end solution for cognitive care.

Key Points: 
  • AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise.
  • "Dr. Greenstein's expertise will be invaluable as we continue to innovate and strengthen our offerings to better serve healthcare professionals, patients, and caregivers," said Kim Rodriguez, CEO of BrainCheck.
  • "In previous roles, Dr. Greenstein led objective evaluations of available cognitive assessment and care planning tools, and concluded that BrainCheck has the highest clinical utility and efficacy.
  • His research validates the clinical utility of our technology and we look forward to continuing to incorporate his expert acumen as we evolve our solutions and accelerate nationwide adoption."

PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Wednesday, January 3, 2024
Trauma, Brain, Research, McLean Hospital, Survivor, PTSD, Assistant, Harvard Medical School

New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at 2:00 pm ET.

Key Points: 
  • New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at 2:00 pm ET.
  • The presenter will be Nathaniel G. Harnett, Ph.D., Director of the NATE Lab at McLean Hospital and Assistant Professor in Psychiatry at Harvard Medical School.
  • The webinar will be hosted by Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds.
  • This webinar will highlight emerging research supported by BBRF that has begun to identify the brain circuits that contribute to PTSD susceptibility and may be used to predict future PTSD symptoms.

Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, November 15, 2023
CNS, Medicine, Johnson & Johnson, Psychiatry, Geriatric psychiatry, Dartmouth College, Lasser, DSM-IV codes, Patient, M.B.A, Mental health, Neurodegenerative disease, Binge eating disorder, Novartis, University, CMO, Roche, Noema, Neurology, McLean Hospital, Pharmaceutical industry, Biochemistry

BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO).

Key Points: 
  • BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO).
  • Lasser brings over 25 years of CNS experience with a successful track record of medical leadership for neuroscience development and commercialization, and I am excited to welcome him to our leadership team,” said Ilise Lombardo, M.D., Chief Executive Officer Noema.
  • Before that, he was the Chief Medical Officer at MedDay Pharma.
  • Working with the dedicated team at Noema to bring novel therapies to those fighting devastating CNS conditions is part of that continuing devotion.”

Hightop Health Adds Industry Veteran to Board of Directors

Retrieved on: 
Thursday, December 14, 2023
Mental Health, Health, Practice Management, Health Technology, Managed Care, High-top, Mass General Brigham, Acquisition, Mass, Multimedia, Patient, News, Trustee, Vallone, Harvard Medical School, Partnership, McLean Hospital, MGB, Management, Nursing

Hightop Health , a premier outpatient mental health platform, today announced the appointment of Carol Vallone as its Independent Board Director.

Key Points: 
  • Hightop Health , a premier outpatient mental health platform, today announced the appointment of Carol Vallone as its Independent Board Director.
  • View the full release here: https://www.businesswire.com/news/home/20231214543962/en/
    Carol Vallone, seasoned CEO and McLean Hospital Board Chair, was today announced as Hightop Health's first Independent Board Director.
  • With its launch, Hightop aimed to gather the best minds in the industry to speak into Hightop’s strategy and approach, including a Board of Directors and Clinical Advisory Board, with Carol Vallone being its first Independent Board Director.
  • Her work and partnership with clinical leaders paired with her understanding of the behavioral health industry lends itself to furthering the Hightop mission.

Borden Cottage Transitions to Independent Ownership

Retrieved on: 
Thursday, October 26, 2023
LCPC, Insurance, Harvard Medical School, McLean Hospital, SVP, Business development, CCS, Environment, Nursing

CAMDEN, Maine, Oct. 26, 2023 /PRNewswire/ -- Borden Cottage , a luxury residential drug, alcohol, and co-occurring behavioral health treatment program located in Camden, Maine, has transitioned to an independent ownership and operational structure, effective October 1.

Key Points: 
  • CAMDEN, Maine, Oct. 26, 2023 /PRNewswire/ -- Borden Cottage , a luxury residential drug, alcohol, and co-occurring behavioral health treatment program located in Camden, Maine, has transitioned to an independent ownership and operational structure, effective October 1.
  • Since its establishment in 2015, Borden Cottage has been transforming lives on the stunning Fox Hill estate, providing treatment for addiction and co-occurring conditions.
  • Under the clinical oversight of Harvard Medical School-affiliated McLean Hospital, Borden Cottage established a strong foundation and reputation as a leader in the industry.
  • The entire team, composed of seasoned Borden Cottage staff, is committed to elevating the program's world-class treatment services.

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Mass General Brigham, Buprenorphine, Opioid use disorder, Harvard Medical School, IND, Drug, McLean Hospital, Assistant, U.S. government and smoking cessation, Psychiatry, Doctor of Philosophy, Naltrexone, Methadone, Development, OUD, National Institute on Drug Abuse, NIDA, Immunoglobulin G, Research and development, Blood, Brain, Mass, Therapy, Fentanyl, Bangladesh Technical Education Board, Pharmaceutical industry

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Rippl and McLean Hospital collaborate to build 'first of its kind' dementia training program

Retrieved on: 
Monday, October 9, 2023
Partnership, Social, McLean Hospital, Research, Alzheimer's disease, Dementia, MD, Caregiver, Mass, Mass General Brigham, Disease, Mental health, Alzheimer's Association, History, Access, Curriculum, Health equity, Patient, Quality of life, Practitioner, Nursing, Ripples Foundation

SEATTLE, Oct. 9, 2023 /PRNewswire/ -- Today Rippl proudly announces a groundbreaking partnership with McLean Hospital, a member of Mass General Brigham to dramatically improve the training and development of a specialty workforce to care for seniors with dementia and other neurocognitive diseases. 

Key Points: 
  • The curriculum and training developed through this collaboration will be housed exclusively in Rippl Academy, Rippl's in-house dementia training program.
  • Development is focused in four key areas:
    Expertise and Training: Central to this collaboration is the development of the proprietary Foundational Dementia Training Series, exclusively designed for Rippl clinicians.
  • By adopting research-informed, evidence-based practices, McLean Hospital and Rippl are committed to delivering the most effective and compassionate care to seniors living with dementia.
  • By proactively addressing seniors' mental health needs, McLean Hospital and Rippl aim to enhance the overall quality of life for this vulnerable population.

AceUp and The Institute of Coaching (IOC) Launch Research Consortium on Human-Centered Leadership

Retrieved on: 
Tuesday, July 11, 2023
Consulting, Other Professional Services, Professional Services, Thought Leadership, Science, Harvard Medical School, Organization, Dyad, Hope, Research, IOC, McLean Hospital, Doctor of Philosophy, Management

AceUp, the leading provider of human-centered leadership development coaching solutions, announced today a 5-year commitment with The Institute of Coaching (IOC) at McLean Hospital, a Harvard Medical School affiliate, to launch a research consortium focusing on human-centered leadership.

Key Points: 
  • AceUp, the leading provider of human-centered leadership development coaching solutions, announced today a 5-year commitment with The Institute of Coaching (IOC) at McLean Hospital, a Harvard Medical School affiliate, to launch a research consortium focusing on human-centered leadership.
  • With AceUp as its founding benefactor, the human-centered leadership consortium will bring some of the most prominent thought-leaders together to examine the impacts and outcomes of leadership behaviors across organizations and defining a science and data-backed blueprint for leadership excellence in a new world of work.
  • “AceUp is honored to take a leading role in this important journey to help further define, exhibit and expand the immense benefits of human-centered leadership,” said Will Foussier, CEO, AceUp.
  • The first phase will last a year and will be spent working to determine a scientific definition of human-centered leadership as well as determining how coaching can unleash human-centered leadership.

Melmark New England Celebrates Twenty-Five Years of Mission First Moments Serving Individuals with Autism, Intellectual and Developmental Disabilities

Retrieved on: 
Thursday, June 1, 2023
ABA, Massachusetts Association for the Blind and Visually Impaired, Berklee College of Music, WCVB, DSP, Citation, Spectrum, Woman, Applied behavior analysis, Multimedia, Disability studies, Axis, Organization, Congress, News presenter, MD, Brain, Intellectual, McLean Hospital, Gerald Loeb Lifetime Achievement Award winners, MAGIC, CARES Act, Commonwealth, Nursing, Management

Leading the evening's ceremonies, nearly 300 guests also enjoyed co-emcees Cindy Fitzgibbon of WCVB StormTeam 5 and Kendra Petrone, MAGIC 106.7's morning co-host.

Key Points: 
  • Leading the evening's ceremonies, nearly 300 guests also enjoyed co-emcees Cindy Fitzgibbon of WCVB StormTeam 5 and Kendra Petrone, MAGIC 106.7's morning co-host.
  • Thomas Crofcheck, Vice President and Chief Financial Officer, shared his thoughts on the state of employee wages.
  • Crofcheck said "Human services organizations rely on direct support professionals who are predominantly women, people of color, and immigrants.
  • Despite the fact that some public funding agencies do not support annual DSP wage increases, Rita did it anyway.